Greenwich LifeSciences, Inc. SEC filings GLSI
Greenwich LifeSciences, Inc. has 279 filings in SEC EDGAR's recent list, going back to Jan 27, 2020. Its latest annual report, Form ARS, was filed on Oct 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Dec 18, 2025 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Oct 26, 2026 | — |
| DEF 14A | Proxy statement | Oct 26, 2026 | Oct 26, 2026 |
| DEFA14A | Additional proxy material | Nov 3, 2025 | — |
| DEF 14A | Proxy statement | Nov 3, 2025 | Nov 3, 2025 |
| DEFA14A | Additional proxy material | Nov 1, 2024 | — |
| DEF 14A | Proxy statement | Nov 1, 2024 | Nov 1, 2024 |
| DEFA14A | Additional proxy material | Oct 25, 2023 | — |
| DEF 14A | Proxy statement | Oct 25, 2023 | Oct 24, 2023 |
| DEFA14A | Additional proxy material | Oct 19, 2022 | — |
| DEF 14A | Proxy statement | Oct 19, 2022 | Oct 19, 2022 |
| DEFA14A | Additional proxy material | Oct 20, 2021 | — |
| DEF 14A | Proxy statement | Oct 19, 2021 | Oct 19, 2021 |
Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GLSI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Stafford, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1799788
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.